Is Vandetanib available in China?

Vandetanib (Vandetanib) is a cancer drug that can interfere with the growth and spread of cancer cells in the body. It is sold overseas under the trade name Caprelsa and can be used to treat thyroid cancer in adults. Vandetanib is only available from certified pharmacies under a special program called the Caprelsa REMS program. Patients must be registered in the program and understand the risks of taking the drug before they may use it under the guidance of a doctor.

The active substance in vandetanibvandetanib is a "protein tyrosine kinase inhibitor". This means that it blocks tyrosine kinase activity. These enzymes are required for certain receptors on the surface of cancer cells, such as the VEGF, EGF and RET receptors, where they activate several processes including cell division and the growth of new blood vessels. By blocking the activity of VEGF receptors, the drug reduces the blood supply to cancer cells and slows cancer growth. By blocking the activity of the EGF receptor, cancer cells no longer receive the information they need to grow and multiply. Vandetanib also blocks the activity of the RET receptor, which plays a role in the growth of medullary thyroid cancer cells.

The original drug vandetanib has not yet passed the relevant regulations of the State Food and Drug Administration for marketing in China, and therefore is not included in the medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.